Personalized Health Monitoring

Glucose

SpO2

Blood Pressure

HR / HRV

Non-Communicable Diseases like Diabetes and Hypertension are the largest cause of death worldwide. Our needle-free technology allows to check your health by tracking key biomarkers through light and AI

Our Technology

Molecular Light Absorbance

Viit Health’s technology uses Molecular Light Absorbance to detect biomarkers by analyzing how visible and near-infrared (NIR) light interacts with tissue. Specific molecular bonds—such as O-H, C-H, and N-H—absorb light at characteristic wavelengths. By capturing these absorbance patterns, the system can estimate concentrations of key biomolecules like glucose and oxygenated hemoglobin, enabling non-invasive and real-time physiological monitoring.

Light Rotation

Some biomolecules, like glucose, can rotate the plane of polarized light—a property called optical activity. Viit Health leverages this phenomenon by sending polarized light into tissue and measuring its rotation after interaction with optically active compounds. This adds a complementary layer of molecular insight to absorbance and PPG data.

Photoplethysmography (PPG)

Photoplethysmography (PPG) is an optical technique that tracks blood volume changes in the skin’s microvascular tissue. As the heart beats, blood flow alters the amount of light absorbed and reflected. Our device captures these variations to derive cardiovascular metrics such as heart rate, oxygen saturation, and vascular health, all without needles or cuffs.

Artificial Intelligence

Viit Health’s AI engine turns complex optical signals into accurate health insights using advanced proprietary models that implement ensemble processes like Gaussian Process Regression along with Recurrent Neural Networks. Trained on thousands of patient measurements, these models personalize results and detect early signs of health risks, enabling smarter, data-driven prevention and care.

Invest in your health

Non-Invasive

By leveraging light-based technologies, Viit Health enables rapid, needle-free measurement of key biomarkers. This reduces patient discomfort and simplifies routine monitoring, making it ideal for preventive care.

Comprehensive

The device delivers immediate readings for multiple parameters—glucose, heart rate, oxygen saturation, blood pressure, and more—supporting timely, informed clinical decisions during consultations or screenings.

Personalized

AI models adapt to each patient’s physiology and demographic context, improving accuracy over time, enabling early detection of individual health risks, and supporting personalized health improvement recommendations.

Accessible

Compact, significantly cost-effective, and easy to use, the system eliminates reliance on consumables and enables scalable preventive care across primary care clinics, mobile units, home settings, and underserved communities.

Get Involved

Clinical and Product Validation

Clinical Research

Since 2018, we’ve conducted multiple calibration and clinical validation protocols in collaboration with leading healthcare institutions across the U.S. and Mexico. We are currently completing our fourth clinical study and have validated our technology in over 3,700 individuals. Over the next 18 months, we plan to conduct three additional robust trials to expand our clinical evidence foundation, support regulatory pathways, and ensure effectiveness across diverse patient populations and clinical settings.

Product Development

Our patent-pending technology is advancing toward market approval, supported by four R&D grants and targeted investment. Over the past seven years, we’ve developed four product iterations informed by clinical insights, user feedback, and rigorous testing. We work closely with leading manufacturing and product development firms in the U.S. and Europe, and collaborate with specialized optical sensor partners to ensure scalable, high-performance solutions that align with global regulatory standards.

Mexican Juarez Hospital

Mexican Juarez Hospital

Hospital Juárez de México (HJM)
May 2025 – Present

Comparative Observational Study focused on Glucose, Blood Pressure, SpO2 and Heart Rate Variability. Cross-sectional analysis of 1,000 patients and longitudinal study of 117 patients.

Fourth product iteration (current device).
General Hospital of Mexico

General Hospital of Mexico

Hospital General de México Dr. Eduardo Liceaga (HGM)
June 2024 – present

Comparative Observational Study. Cross-sectional analysis of 1,350 patients focused on Glucose, Blood Pressure, SpO2 and Heart Rate Variability.

Fourth product iteration (current device).
National Institute of Nutrition

National Institute of Nutrition

Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMNSZ)
2019 – 2021

Comparative Observational Study focused on glucose measurement. Cross-sectional analysis of 2,200 patients.

Third product iteration (predecessor device).
Mexico City's Health Department

Specialized Diabetes Clinics

Secretaría de Salud de la Ciudad de México (SEDESA)
2019 – 2020

Multi-centric Comparative Observational Study focused on glucose measurement. Cross-sectional analysis of 1,200 patients.

Third product iteration (predecessor device).
Demo for President Claudia Sheinbaum (MX)

Mexican Government Support

Secretaría de Ciencia, Humanidades, Tecnología e Innovación (SECIHTI)
2018 – 2021

We have been awarded four research and development grants and institutional support from Mexico City’s government (SECTEI & SEDESA) and the National Council of Science and Technology (CONAHCYT).

Third product iteration (predecessor device).

Help us reshape the future of healthcare

0

Deaths per year due to NCDs

Non Communicable Diseases (NCDs) are the largest cause of death around the world, accounting for 70% of deaths (7 out of 10 people). Cardiovascular diseases account for at least 19 million deaths, followed by cancers (10 million), chronic respiratory diseases (4 million), and diabetes (over 2 million including kidney disease deaths caused by diabetes).

0

of NCDs are Preventable

Most NCDs are preventable, yet current strategies fall short due to the lack of accessible, real-time health monitoring data, inefficiencies of traditional health assessments in producing relevant health insights, and financial constraints faced by national and regional health programs due to costly measurements that limit the deployment of comprehensive prevention schemes.

0

Diabetics by 2030

It is estimated that 643 million people in the world will have diabetes by 2030, and that number is expected to rise to 783 million by 2045. We are in urgent need of massive prevention campaigns that can deploy improved monitoring technologies to provide actionable and personalized recommendations.

0

NCD Global Economic Burden

Global spending on NCDs will reach staggering heights by 2030. Concurrently, the International Diabetes Federation estimates the healthcare cost associated to diabetes at a minimum of $966 billion dollars per year. If more accesible prevention devices were to be implemented, the cost could decrease drastically.